iBio, Inc. Common Stock (IBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $51.55M
Last updated: Nov 17, 2026 at 11:06 AM ET
iBio, Inc. Common Stock (IBIO) Financials: Revenue, Profit and Cash Flow
iBio, Inc. Common Stock reported revenue of $100.00K for the fiscal year ended Jun 30, 2026, down 75.0% from the year before. That year, net income was -$33.04M with a net margin of -33044.0%, operating cash flow was -$23.22M and free cash flow was -$23.80M. The quarter ended Jun 30, 2026 had net income of -$10.60M.
Revenue and Margins
Over the 9 years to Jun 2026, revenue fell from $394.00K, a compound annual decline of 14.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $100.00K | -75.0% | 100.0% | -35141.0% | -33044.0% |
| Jun 2025 | $400.00K | +77.8% | 100.0% | -4650.5% | -4594.3% |
| Jun 2024 | $225.00K | N/A | 100.0% | -7392.9% | -11069.8% |
| Jun 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Jun 2022 | $1.88M | -20.5% | 100.0% | -1576.3% | -2670.1% |
| Jun 2021 | $2.37M | +44.7% | 38.3% | -1312.1% | -979.0% |
| Jun 2020 | $1.64M | -18.8% | 57.1% | -854.9% | -1003.9% |
| Jun 2019 | $2.02M | +354.5% | 100.0% | -782.4% | -872.0% |
| Jun 2018 | $444.00K | +12.7% | 100.0% | -3204.3% | -3627.9% |
| Jun 2017 | $394.00K | N/A | 100.0% | -3622.8% | -4096.2% |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.00K | $400.00K | $225.00K | $0 | $1.88M | $2.37M | $1.64M | $2.02M | $444.00K | $394.00K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $1.46M | $703.00K | $0 | $0 | $0 |
| Gross profit | $100.00K | $400.00K | $225.00K | $0 | $1.88M | $909.00K | $935.00K | $2.02M | $444.00K | $394.00K |
| Research and development | $19.64M | $8.31M | $5.18M | $10.33M | $9.83M | $9.99M | $3.57M | $5.47M | $3.99M | $4.12M |
| Operating income | -$35.14M | -$18.60M | -$16.63M | -$29.34M | -$29.70M | -$31.11M | -$14.00M | -$15.79M | -$14.23M | -$14.27M |
| Net income | -$33.04M | -$18.38M | -$24.91M | -$65.01M | -$50.30M | -$23.21M | -$16.44M | -$17.60M | -$16.11M | -$16.14M |
| EBITDA | -$34.30M | -$17.48M | -$14.26M | -$28.23M | -$25.49M | -$19.93M | -$11.76M | -$14.04M | -$12.52M | -$12.60M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $100.00K | $200.00K | $0 | $200.00K | $0 | $175.00K | $0 | $0 | $50.00K |
| Gross profit | N/A | $0 | $0 | $100.00K | $200.00K | $0 | $200.00K | $0 | $175.00K | $0 | $0 | $50.00K |
| Operating income | -$11.38M | -$8.37M | -$9.45M | -$5.95M | -$5.20M | -$4.88M | -$4.42M | -$4.11M | -$3.41M | -$3.63M | -$4.50M | -$5.10M |
| Net income | -$10.60M | -$7.73M | -$8.99M | -$5.72M | -$5.16M | -$4.86M | -$4.36M | -$3.99M | -$7.78M | -$3.17M | -$8.21M | -$5.75M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded short-term debt of $0 by $56.40M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $99.11M | $23.18M | $28.73M | $41.21M | $99.41M | $146.97M | $94.19M | $30.59M | $43.08M | $36.01M |
| Current assets | $92.22M | $9.72M | $15.67M | $26.26M | $45.07M | $104.60M | $61.75M | $4.81M | $16.29M | $8.57M |
| Cash and equivalents | $56.40M | $8.58M | $14.21M | $4.30M | $22.68M | $77.40M | $55.11M | $4.42M | $15.93M | $8.09M |
| Total liabilities | $13.40M | $8.30M | $7.41M | $25.83M | $35.92M | $38.40M | $37.58M | $28.13M | $26.92M | $27.09M |
| Short-term debt | $0 | $830.00K | $519.00K | $13.10M | $22.16M | $600.00K | $261.00K | $213.00K | $197.00K | $183.00K |
| Long-term debt | N/A | N/A | $829.00K | $241.00K | N/A | $0 | $339.00K | $0 | $24.88M | $25.08M |
| Shareholder equity | $85.71M | $14.88M | $21.32M | $15.38M | $63.48M | $108.58M | $56.62M | $2.46M | $16.17M | $8.91M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $99.11M | $85.83M | $64.39M | $64.16M | $23.18M | $19.10M | $21.70M | $24.52M | $28.73M | $50.15M | $34.02M | $37.68M |
| Total liabilities | $13.40M | $8.30M | $7.83M | $8.12M | $8.30M | $7.72M | $7.80M | $6.76M | $7.41M | $25.29M | $24.82M | $24.47M |
| Cash and equivalents | $56.40M | $47.63M | $28.67M | $28.11M | $8.58M | $4.96M | $7.01M | $11.04M | $14.21M | $5.30M | $2.79M | $1.46M |
| Shareholder equity | $85.71M | $77.54M | $56.56M | $56.04M | $14.88M | $11.38M | $13.89M | $17.75M | $21.32M | $24.86M | $9.20M | $13.21M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.22M | -$15.30M | -$18.55M | -$30.44M | -$37.48M | -$30.06M | -$13.35M | -$13.97M | -$13.48M | -$13.16M |
| Capital expenditures | $578.00K | $16.00K | $210.00K | $5.74M | $7.33M | $4.92M | $1.08M | $920.00K | $934.00K | $1.32M |
| Free cash flow | -$23.80M | -$15.32M | -$18.76M | -$36.17M | -$44.81M | -$34.98M | -$14.42M | -$14.89M | -$14.41M | -$14.49M |
| Dividends paid | N/A | N/A | N/A | $39.00K | $50.00K | $0 | $21.56M | N/A | $0 | $0 |
| Share repurchases | $5.86M | $294.00K | N/A | $0 | N/A | $4.71M | $2.17M | $159.00K | $1.18M | $0 |
| Investing cash flow | -$32.00M | $742.00K | $906.00K | $7.01M | -$5.13M | -$26.48M | -$1.15M | -$990.00K | -$1.08M | -$1.59M |
| Financing cash flow | $103.05M | $8.93M | $24.49M | $2.30M | -$6.13M | $78.83M | $65.19M | $3.45M | $22.41M | -$170.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.23M | -$6.08M | -$5.24M | -$5.67M | -$4.62M | -$3.10M | -$3.87M | -$3.71M | -$4.85M | -$3.65M | -$4.71M | -$5.34M |
| Capital expenditures | $19.00K | $11.00K | $516.00K | $32.00K | $1.00K | $14.00K | $1.00K | $0 | $210.00K | $0 | $50.00K | $50.00K |
| Free cash flow | -$6.25M | -$6.09M | -$5.76M | -$5.70M | -$4.62M | -$3.12M | -$3.87M | -$3.71M | -$5.06M | -$3.65M | -$4.76M | -$5.39M |
Frequently Asked Questions About IBIO
What is iBio, Inc. Common Stock's annual revenue?
iBio, Inc. Common Stock reported revenue of $100.00K for the fiscal year ended Jun 30, 2026.
How fast is iBio, Inc. Common Stock's revenue growing?
Revenue was down 75.0% for the fiscal year ended Jun 30, 2026 compared with the year before.
Is iBio, Inc. Common Stock profitable?
No. iBio, Inc. Common Stock reported net income of -$33.04M for the fiscal year ended Jun 30, 2026, with a net margin of -33044.0%.
How much free cash flow does IBIO generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of -$23.22M minus capital expenditures of $578.00K produced free cash flow of -$23.80M.
How much debt does iBio, Inc. Common Stock have?
The balance sheet dated Jun 30, 2026 reported short-term debt of $0 and cash and equivalents of $56.40M.
IBIO pages: Overview, Earnings, Forecast, Financials, Competitors